Should I Buy PRQR? PRQR 2026 Analysis

Should You Buy ProQR Therapeutics NV (PRQR) Today? Analysis, Price Targets, and 2026 Outlook.

No data

Growth

Profitability

Efficiency

3 Analyst Rating

Wall Street analysts forecast PRQR stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.570

Low

Averages

8.67

High

Current: 1.570

Low

Averages

8.67

High

Oppenheimer

Kostas Biliouris

Outperform

initiated

AI Analysis

2026-03-12

Reason

Oppenheimer

Kostas Biliouris

Price Target

AI Analysis

2026-03-12

initiated

Outperform

Reason

Oppenheimer analyst Kostas Biliouris assumed coverage of ProQR Therapeutics with an Outperform rating and $9 price target. The firm sees a lot to like for ProQR shares based on positive key opinion leader feedback ahead of the first half of 2026 target engagement data for AX-0810 in HV. Strong preclinical data support ProQR's RNA editing platform, and its KOL indicated that the company's unique approach could address the significant unmet need across 100K patients without available treatments in primary sclerosing cholangitis and bilary atresia.

Evercore ISI

Outperform

maintain

$4 -> $5

2025-07-11

Reason

Evercore ISI

Price Target

$4 -> $5

2025-07-11

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on ProQR Therapeutics to $5 from $4 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRQR

Unlock Now

PRQR Should I Buy

PRQR Should I Buy

Should You Buy ProQR Therapeutics NV (PRQR) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch